Búsqueda | Portal de Búsqueda de la BVS España

Mahil, S K; Yates, M; Langan, S M; Yiu, Z Z N; Tsakok, T; Dand, N; Mason, K J; McAteer, H; Meynell, F; Coker, B; Vincent, A; Urmston, D; Vesty, A; Kelly, J; Lancelot, C; Moorhead, L; Bachelez, H; Bruce, I N; Capon, F; Contreras, C R; Cope, A P; De La Cruz, C; Di Meglio, P; Gisondi, P; Hyrich, K; Jullien, D; Lambert, J; Marzo-Ortega, H; McInnes, I; Naldi, L; Norton, S; Puig, L; Sengupta, R; Spuls, P; Torres, T; Warren, R B; Waweru, H; Weinman, J; Griffiths, C E M; Barker, J N; Brown, M A; Galloway, J B; Smith, C H.

Br J Dermatol; 185(1): 80-90, 2021 07.

Artículo en Inglés | MEDLINE | ID: mdl-33368145

15.

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.

Warren, R B; Hansen, J B; Reich, K; Paul, C; Puig, L.

J Eur Acad Dermatol Venereol; 35(2): 450-457, 2021 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-32662540

16.

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.

Reich, K; Hansen, J B; Puig, L; Konstantinou, M P; Warren, R B.

J Eur Acad Dermatol Venereol; 35(10): 2034-2044, 2021 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-34076919

17.

Definition of minimal disease activity in psoriasis.

Carretero, G; Carrascosa, J M; Puig, L; Sánchez-Carazo, J L; López-Ferrer, A; Cueva, P; Soria, C; Rivera, R; Belinchón, I.

J Eur Acad Dermatol Venereol; 35(2): 422-430, 2021 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-32367536

18.

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.

Beecker, J; Papp, K A; Dutz, J; Vender, R B; Gniadecki, R; Cooper, C; Gisondi, P; Gooderham, M; Hong, C H; Kirchhof, M G; Lynde, C W; Maari, C; Poulin, Y; Puig, L.

J Eur Acad Dermatol Venereol; 35(4): 797-806, 2021 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-33533553

19.

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.

Diels, J; Thilakarathne, P; Cameron, C; McElligott, S; Schubert, A; Puig, L.

Br J Dermatol; 183(2): 276-284, 2020 08.

Artículo en Inglés | MEDLINE | ID: mdl-31652347

20.

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.

Reich, K; Puig, L; Szepietowski, J C; Paul, C; Lacour, J P; Tsianakas, A; Sieder, C; Rissler, M; Pournara, E; Orsenigo, R.

Br J Dermatol; 182(2): 304-315, 2020 02.

Artículo en Inglés | MEDLINE | ID: mdl-31102257

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.

Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology.

Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis. / Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave.

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.

Prevalence of most common skin diseases in Europe: a population-based study.

Nail Psoriasis. / Psoriasis ungueal.

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.